SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:d137edd3-48d0-4461-bba0-993b79d70dd7"
 

Search: onr:"swepub:oai:lup.lub.lu.se:d137edd3-48d0-4461-bba0-993b79d70dd7" > Deep, rapid, and du...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Chowdhury, S.King's College London (author)

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • Elsevier BV,2023
  • 9 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:d137edd3-48d0-4461-bba0-993b79d70dd7
  • https://lup.lub.lu.se/record/d137edd3-48d0-4461-bba0-993b79d70dd7URI
  • https://doi.org/10.1016/j.annonc.2023.02.009DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background: The first interim analysis of the phase III, randomized, double-blind, placebo-controlled, multinational TITAN study demonstrated improved overall survival (OS) and radiographic progression-free survival (rPFS) with apalutamide added to ongoing androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer. The final analysis confirmed improvement in OS and other long-term outcomes. We evaluated prostate-specific antigen (PSA) kinetics and the association between PSA decline and outcomes in patients with metastatic castration-sensitive prostate cancer from TITAN. Patients and methods: Patients received apalutamide (240 mg/day) or placebo plus ADT (1: 1). This post hoc exploratory analysis evaluated PSA kinetics and decline in relation to rPFS (22.7 months’ follow-up) and OS, time to PSA progression, and time to castration resistance (44.0 months’ follow-up) in patients with or without confirmed PSA decline using a landmark analysis, the Kaplan–Meier method, and Cox proportional hazards model. Results: One thousand and fifty-two patients (apalutamide, 525; placebo, 527) were enrolled. Best confirmed PSA declines (≥50% or ≥90% from baseline or to ≤0.2 ng/ml) were achieved at any time during the study in 90%, 73%, and 68% of apalutamide-treated versus 55%, 29%, and 32% of placebo-treated patients, respectively. By 3 months of apalutamide treatment, best deep PSA decline of ≥90% or to ≤0.2 ng/ml occurred in 59% and 51% of apalutamide- and in 13% and 18% of placebo-treated patients, respectively. Achievement of deep PSA decline at landmark 3 months of apalutamide treatment was associated with longer OS [hazard ratio (HR) 0.35; 95% confidence interval (CI) 0.25-0.48), rPFS (HR 0.44; 95% CI 0.30-0.65), time to PSA progression (HR 0.31; 95% CI 0.22-0.44), and time to castration resistance (HR 0.38; 95% CI 0.27-0.52) compared with no decline (P < 0.0001 for all). Similar results were observed at landmark 6 and 12 months of apalutamide treatment. Conclusions: Apalutamide plus ADT demonstrated a robust (rapid, deep, and durable) PSA decline that was associated with improved clinical outcomes, including long-term survival.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bjartell, A.Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)kir-abj (author)
  • Agarwal, N.Huntsman Cancer Institute (author)
  • Chung, B. H.Yonsei University (author)
  • Given, R. W.Eastern Virginia Medical School (author)
  • Pereira de Santana Gomes, A. J. (author)
  • Merseburger, A. S.University Medical Center Schleswig-Holstein (author)
  • Özgüroğlu, M.Istanbul University (author)
  • Juárez Soto, Soto (author)
  • Uemura, H.Kindai University Hospital (author)
  • Ye, D.Fudan University Shanghai Cancer Center (FUSCC) (author)
  • Brookman-May, S. D.Ludwig-Maximilian University of Munich,Janssen Research & Development, Belgium (author)
  • Londhe, A.Janssen Research & Development, Belgium (author)
  • Bhaumik, A.Janssen Research & Development, Belgium (author)
  • Mundle, S. D.Janssen Research & Development, Belgium (author)
  • Larsen, J. S.Janssen Research & Development, Belgium (author)
  • McCarthy, S. A.Janssen Research & Development, Belgium (author)
  • Chi, K. N. (author)
  • King's College LondonUrologisk cancerforskning, Malmö (creator_code:org_t)

Related titles

  • In:Annals of Oncology: Elsevier BV34:5, s. 477-4850923-7534

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view